Dorzagliatin

• CAT Number: I006519
• CAS Number: 1191995-00-2
• Molecular Formula: C22H27ClN4O5
• Molecular Weight: 462.93
• Purity: ≥95%
• Synonyms: Dorzagliatin;(2S)-2-[4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-N-{1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl}-4-methylpentanamide
• Target: Glucokinase
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: (2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide
• InChI: InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
• InChIKey: HMUMWSORCUWQJO-QAPCUYQASA-N
• SMILES: CC(C)C[C@@H](C(=O)NC1=NN(C=C1)C[C@H](CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl

Dorzagliatin（Cat No.:I006519）is an investigational oral drug being developed for the treatment of type 2 diabetes. It is a dual agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. By activating the GLP-1 receptor, dorzagliatin helps to increase insulin secretion, reduce glucagon release, and improve glucose homeostasis. Additionally, its action on the glucagon receptor may help improve hepatic glucose production. This dual mechanism aims to enhance blood sugar control and potentially offer benefits like weight loss and improved insulin sensitivity. Clinical trials are ongoing to evaluate its efficacy and safety.